Navigation Links
AlphaVax Announces Promising Results in Melanoma Studies

RESEARCH TRIANGLE PARK, N.C., May 13 /PRNewswire/ -- AlphaVax announced today the presentation of promising results from a collaboration with researchers at the Memorial Sloan-Kettering Cancer Center (MSKCC). Francesca Avogadri, Ph.D., a Research Fellow in the Department of Medicine at MSKCC presented data at the American Association of Immunologists Annual Meeting in Seattle, Washington.

Results from pre-clinical studies conducted at MSKCC demonstrate the ability of AlphaVax's virus-like replicon vector particles (VRP) encoding melanoma-specific tumor antigens to reduce melanoma tumor burden in a state-of-the-art murine melanoma model.

Jedd D. Wolchok, M.D., Ph.D., Lab Head and faculty member at MSKCC, is a medical oncologist who specializes in the treatment of melanoma and in whose laboratory the work was conducted. Dr. Wolchok's research is focused on harnessing the immune system to prevent melanoma from recurring after surgery, as well as more effective treatments for the disease when it does recur. In comparing these results to others that his lab has investigated, Dr. Wolchok commented that "this is the most potent single intervention we have seen in this model."

"We are excited by the results obtained in the studies conducted by Dr. Wolchok's group at MSKCC. Immunotherapeutic intervention with a novel vaccine vector such as ours may prove beneficial as a treatment strategy for patients with melanoma, and we hope to translate these findings into clinical testing in the near future," said Robert Olmsted, Ph.D., Vice President of Research at AlphaVax, Inc.

The American Cancer Society estimates that nearly 62,500 people were diagnosed with melanoma of the skin in 2008, and over 8,400 deaths were due to the disease. While melanoma accounts for a small percent of all skin cancers, it is far more serious than other skin cancers if not detected and treated early. Melanoma is a form of cancer that begins in melanocytes (cells that make the pigment melanin). Current treatment of later-staged melanoma includes surgical removal of the tumor tissue, followed by chemotherapy and/or radiation therapy.

About AlphaVax

AlphaVax, Inc. is a North Carolina-based, clinical-stage company that uses a novel alphavirus vector platform technology that has proven to be highly flexible and immunogenic, and allows the same manufacturing, formulation, and delivery strategies to be applied to many different products. A phase I/II clinical trial for a CEA tumor vaccine is currently ongoing at Duke University and a Her2 breast cancer clinical trial is planned for later this year. In addition to cancer immunotherapy programs, AlphaVax is developing vaccine products for herpes simplex virus, influenza, respiratory syncytial virus, HIV and a number of biodefense targets. The AlphaVax headquarters and R&D facilities are located in Research Triangle Park, and its GMP manufacturing facility is located in Lenoir, NC. The company employs staff with expertise spanning vaccine design, process development, GMP manufacturing, quality assurance, and regulatory and clinical affairs.

SOURCE AlphaVax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. AlphaVax Announces Results From Phase 1 Influenza Vaccine Clinical Trial
2. AlphaVax Announces Initial Analysis of Data From CMV Phase 1 Clinical Trial
3. AlphaVax Continues to Expand the Use of Its Vaccine Platform
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
(Date:11/30/2015)... 30, 2015  PTS Diagnostics, the U.S.-based manufacturer of ... analyzers, A1CNow ® systems, and PTS Detect™ cotinine ... patents that will propel the company into the mHealth ... Europe . The technology is a system ... on smartphones and tablets, and uses test strip technology ...
(Date:11/30/2015)... NASHUA, N.H. , Nov. 30, 2015 /PRNewswire/ ... today that it will feature its latest solutions ... the early identification of cancer at the Radiological ... in Chicago from November ... showcase recent product advances including iReveal®, an automated ...
(Date:11/30/2015)... -- Hanger, Inc. (NYSE: HGR ) (the "Company") today ... its previously announced consent solicitation (as amended and restated, ... amount 7⅛% Senior Notes due 2018 (the "Notes") to ... pursuant to the Consent Solicitation, (ii) the proposed increased ... date of the Consent Solicitation.    ...
Breaking Medicine Technology:
(Date:11/30/2015)... Madeira Beach, FL (PRWEB) , ... November 30, ... ... issue of Consumer Reports magazine, quoted Michael Hansen, Ph.D., a senior scientist at ... exposure, and even more so for a child’s exposure limits. , The original ...
(Date:11/30/2015)... ... November 30, 2015 , ... Medicalis, a ... Radiology Society of North America (RSNA) annual meeting, being held November 29 – ... 2014. Throughout 2015, the company has completed installations for Integrated Delivery Network ...
(Date:11/30/2015)... ... ... It’s inevitable that everyone will experience death in his or her lifetime. ... lives among us. It is your perspective, however, that determines how you view death ... T Sky understands that she may see death more frequently than most. As she ...
(Date:11/30/2015)... ... ... The successful filing of an Investigational New Drug application (IND) is a ... key industry segment, Regis Technologies has decided to sponsor and participate in an XTalks-hosted ... , Federal law does not allow new drugs to cross state lines until it ...
(Date:11/30/2015)... ... ... Scott Newman MD, FACS of New York’s Advanced Plastic ... the New York City area to utilize the new, non-invasive SculpSure™ Laser System ... for fat loss in the abdomen, flanks, and other areas that is completely ...
Breaking Medicine News(10 mins):